Cargando…
Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients
Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer cardio-and reno-protective effects in individuals with or without type 2 diabetes mellitus. Despite mounting evidence suggesting that SGLT2i pro...
Autores principales: | Pham, Phuong-Thu T., Pham, Phuong-Chi T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479656/ https://www.ncbi.nlm.nih.gov/pubmed/37674999 http://dx.doi.org/10.3389/fneph.2022.1014241 |
Ejemplares similares
-
Medical Management of the Kidney Transplant Recipient: Infections and Malignant Neoplasms
por: Pham, Phuong-Thu T., et al.
Publicado: (2010) -
Kidney Transplant Outcomes in Recipients Over the Age of 70
por: Mehta, Jaya, et al.
Publicado: (2023) -
Immune monitoring of allograft status in kidney transplant recipients
por: Han, Hwarang S., et al.
Publicado: (2023) -
SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist
por: Granata, Antonio, et al.
Publicado: (2022) -
Thrombosis Associated With Cytomegalovirus (CMV) in a Kidney Transplant Recipient
por: Wang, Lin, et al.
Publicado: (2021)